Dexcom
As on 23 May, 2025 | 01:29 IST
| Open | 84.83 |
| Previous Close | 84.99 |
| Beta | 0.60 |
| High | 87.00 |
| Low | 84.29 |
| TTM EPS See historical trend | 1.65(-0.60% YoY) |
| 52 Week High | 129.55 |
| 52 Week Low | 57.60 |
| TTM PE See historical trend | 51.40(Low PE) |
| Mkt. Cap ($ Billion) | 33.13 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 85.89 |
| 10 | 85.55 |
| 20 | 81.17 |
| 50 | 73.73 |
| 100 | 78.89 |
| 200 | 75.52 |
Returns
| 1 Week | -1.02% | |
| 1 Month | 27.93% | |
| 3 Months | -4.54% | |
| YTD | 9.07% | |
| 1 Year | -35.02% | |
| 3 Years | 5.60% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| J&J | 175.46 | -0.75 | 422.38 | 16.73 | 10.49 | 2.88 | 177.67/0.00 | 12.33 | Neutral |
| Abbott | 131.38 | -0.06 | 227.99 | 30.70 | 4.28 | 1.87 | 131.66/0.00 | 0.58 | Bearish |
| Boston Scientific | 105.70 | -0.16 | 154.85 | 53.12 | 1.99 | -- | 107.00/0.00 | -0.47 | Bearish |
| Stryker | 389.74 | -0.87 | 148.01 | 38.44 | 10.14 | 0.98 | 395.11/0.00 | 1.21 | Bearish |
| Medtronic | 91.98 | 0.01 | 122.38 | 17.29 | 5.32 | 3.13 | 92.50/0.00 | -1.13 | Bearish |
Market news
- S&P 500 ends lower as Dell and Nvidia dropAugust 30, 2025 10:46 AM
- Dow notches record high as Wall Street cheers Powell's speechAugust 23, 2025 10:31 AM
- Dow ends higher after UnitedHealth gains, other indexes slip on rate cut uncertaintyAugust 16, 2025 11:08 AM
- Stocks slump on latest tariffs, soft jobs dataAugust 2, 2025 11:55 AM
About the company
Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.